Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Galapagos N.V.. (9/11/18). "Press Release: Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis". Foster City, CA & Mechelen.

Organisations Organisation Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
  Organisation 2 Gilead Sciences Inc. (Nasdaq: GILD)
  Group Gilead Sciences (Group)
Products Product filgotinib (GLPG0634)
  Product 2 clinical research
Persons Person McHutchison, John (Gilead 201809 CSO)
  Person 2 Abi-Saab, Walid (Galapagos 201809 CMO)
     


   
Record changed: 2018-09-13

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top